Physician profile
Karen Watson
NPI 1760423909
$3,451.61
in general payments reported to CMS, 2019-2025
39 companies · $692 in 2025
The $692 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $405 · 2021: $614 · 2022: $384 · 2023: $128 · 2024: $417 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $486.14 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Amgen INC. | $304.49 | 2019-2025 | Repatha, Otezla |
| Abbvie INC. | $262.65 | 2019-2025 | |
| Abbott Laboratories | $256.87 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $205.02 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $185.81 | 2020-2025 | |
| Astellas Pharma US INC | $148.48 | 2019-2025 | Veozah |
| Lilly USA, LLC | $118.77 | 2019-2025 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $110.98 | 2019-2020 | |
| Eisai INC. | $107.47 | 2021-2025 | |
| Smith+Nephew, INC. | $103.54 | 2020 | |
| Merck Sharp & Dohme LLC | $101.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $98.60 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $88.49 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.91 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.